Biotechnology

Overview

Biotechnology includes those technological applications that use biological systems, living organisms or derivatives thereof, to make or modify products or processes for specific use.

Our expertise in biotechnology includes, among others:

  • diagnostic tools and methods,
  • methods and tools for molecular screening,
  • genetics, genomics and proteomics,
  • industrial biotechnology including bioprocessing, biomaterials, biofuels, and enzymes for industrial applications,
  • biological pesticides and insecticides,
  • cell and tissue engineering, and
  • bioinformatics tools.

Biotechnology

 

Biotechnology includes those technological applications that use biological systems, living organisms or derivatives thereof, to make or modify products or processes for specific use.

Our expertise in biotechnology includes, among others:

  • diagnostic tools and methods,
  • methods and tools for molecular screening,
  • genetics, genomics and proteomics,
  • industrial biotechnology including bioprocessing, biomaterials, biofuels, and enzymes for industrial applications,
  • biological pesticides and insecticides,
  • cell and tissue engineering, and
  • bioinformatics tools.
 
 

In particular, we have developed greater expertise in:

  • bio-agronomy and nutrition,
  • biomarkers, including methods, agents and diagnostic kits,
  • bioremediation,
  • biosensors,
  • cell and tissue transplantation,
  • genetic engineering: transgenic plants and animals and gene therapy,
  • methods and tools for detection of biomolecules (nucleic acids, proteins, mediators),
  • methods and tools for RNA interference,
  • molecular pharmacology,
  • nanostructures,
  • natural product extracts,
  • organogenesis and regenerative medicine,
  • peptidomimetics and peptides, recombinant proteins, antibodies and hybridomas,
  • therapeutic targets, and
  • tools and methods related to reproduction, including fertility and paternity testing.
  1. Lavery represents ImmunoPrecise Antibodies as it acquires BioStrand

    On March 29, 2022, ImmunoPrecise Antibodies Ltd (IPA) announced that it acquired BioStrand BV, BioKey BV, and BioClue BV (together, “BioStrand”), a group of Belgian entities pioneers in the field of bioinformatics and biotechnology. With this €20 million acquisition, IPA will be able to leverage BioStrand’s revolutionary AI-powered methodology to accelerate the development of therapeutic antibody solutions. In addition to creating synergies with its subsidiaries, IPA expects to develop new markets with this revolutionary technology and strengthen its position as a world leader in biotherapeutics. Lavery was privileged to support IPA in this cross-border transaction by providing specialized expertise in cybersecurity, intellectual property, securities and mergers and acquisitions. The Lavery team was led by Selena Lu (transactional) and included Eric Lavallée (technology and intellectual property), Serge Shahinian (intellectual property), Sébastien Vézina (securities), Catherine Méthot (transactional), Jean-Paul Timothée (securities and transactional), Siddhartha Borissov-Beausoleil (transactional), Mylène Vallières (securities) and Marie-Claude Côté (securities). ImmunoPrecise Antibodies Ltd. is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases.

    Read more